Agile Therapeutics Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 6/2/2024)
| Balance Sheet | Total Assets | 10,255,000.00 | ROE | – |
| Balance Sheet | Total Equity | -16,318,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -200,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -9,777,000.00 | – | – |
| Cashflow | Operating Cash Flow | -9,577,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -6.71 | Div. Yield | – |
| Income | Net Income | -14,465,000.00 | P/E | – |
| Income | Shares Outstanding | 2,156,730.00 | P/B | – |
| Income | Total Revenue | 19,975,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.agiletherapeutics.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more